Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria

2018-01-22T21:32:21+00:00January 22nd, 2018|News|

DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today the confirmation and approval by the European Commission of Ciclopirox (AMP-L2.7.D7) as an Orphan Medicinal Product (OMP) for the treatment of Congenital Erythropoietic Porphyria. This is a follow up on the favourable report by the European Medicine Agency that was announced last December.

The favourable report from the European Medicines Agency and the approval of Ciclopirox as OMP by the European Commission are very important steps in the development of Ciclopirox for the treatment of Congenital Erythropoietic Porphyria. “ATLAS will continue with plans for the development of Ciclopirox. The new OMP status will facilitate the process and ultimately contribute to our goal of delivering Ciclopirox to patients suffering from Congenital Erythropoietic Porphyria at the earliest time possible”, said Dr. Emilio Díez, CEO and CSO of Atlas.

Dr. Oscar Millet, Director of the Laboratory of Protein Stability and Inherited Disease of the CIC bioGUNE, said that “understanding the molecular mechanism of this disease has enabled us to design a therapy based on pharmacological chaperones, molecules that bind to the defective protein fixing its stability problem and reversing its pathogenic effects”.

The EMA´s Orphan Medicinal Product program provides orphan status to drugs and biologics that are being developed to address rare diseases or disorders that affect less than five people in every 10,000 in Europe. With the designation of L2.7.D7 as Orphan Medicinal Product, Atlas will qualify for various incentives that will facilitate the launching of clinical trials on patients in the near future. These incentives include scientific advice and high-quality clinical trial protocol assistance, leading to effective and acceptably safe medicines for the benefit of patients.

This is the first time that an Orphan Medicinal Product has been approved by the European Commission in the Basque Country.

About Congenital Erythropoietic Porphyria
Congenital erythropoietic porphyria (CEP) is a very rare inherited metabolic disorder resulting from the deficient function of the enzyme uroporphyrinogen lll cosynthase (UROS), the fourth enzyme in the heme biosynthetic pathway. Due to the impaired function of this enzyme, excessive amounts of particular porphyrins accumulate, particularly in the bone marrow, plasma, red blood cells, urine, teeth, and bones. The major symptom of this disorder is hypersensitivity of the skin to sunlight and some types of artificial light, bone loss, and deformities. Available treatments only relieve the symptomathology and currently there is no curative therapy for this disease.
http://www.porphyriafoundation.com